Brokers Set Expectations for KROS FY2024 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Keros Therapeutics in a report released on Thursday, October 24th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of ($5.10) for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.88) per share.

Several other equities analysts also recently commented on the stock. Bank of America dropped their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. Scotiabank began coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 target price for the company. Finally, Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a "buy" rating and a $96.00 target price for the company. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $89.11.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded down $0.03 during trading on Monday, hitting $60.73. The company's stock had a trading volume of 302,359 shares, compared to its average volume of 368,907. The business has a 50 day moving average price of $55.18 and a two-hundred day moving average price of $51.82. The company has a market capitalization of $2.28 billion, a PE ratio of -11.84 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the previous year, the business earned ($1.27) EPS.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its stake in shares of Keros Therapeutics by 8.8% during the first quarter. Principal Financial Group Inc. now owns 7,063 shares of the company's stock worth $468,000 after acquiring an additional 574 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 1.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company's stock worth $870,000 after buying an additional 251 shares during the period. FORA Capital LLC acquired a new position in Keros Therapeutics during the first quarter worth about $561,000. GSA Capital Partners LLP grew its position in Keros Therapeutics by 25.5% during the first quarter. GSA Capital Partners LLP now owns 8,538 shares of the company's stock worth $565,000 after buying an additional 1,736 shares during the period. Finally, Swiss National Bank grew its position in Keros Therapeutics by 22.0% during the first quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $3,303,000 after buying an additional 9,000 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the company's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company's stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.90% of the stock is owned by corporate insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.